Strictly analyzed via ultra-high performance liquid chromatography (HPLC) and high-resolution mass spectrometry (HRMS) to guarantee sequence fidelity and minimum impurity profiles.
Addressing the post-antibiotic era requires an engineering paradigm shift from small-molecule cytotoxic antibiotics toward structurally stable, membrane-disruptive, and immunomodulatory Antimicrobial Peptides (AMPs).
According to the World Health Organization (WHO), antimicrobial resistance represents one of the top ten public health threats facing humanity. Traditional small-molecule antibiotics rely on specific biological receptors, enzymatic inactivation targets, or ribosomal protein synthesis machinery. Consequently, continuous horizontal gene transfer and point mutations in bacterial pathogens (including MRSA, VRE, and multidrug-resistant Pseudomonas aeruginosa) rapidly render conventional chemotherapies ineffective.
Synthetic Antibiotic Peptides (Antimicrobial Peptides - AMPs) function via physical electrostatic disruption of negatively charged bacterial cell membranes (through the 'carpet', 'toroidal pore', or 'barrel-stave' mechanisms) or via secondary intracellular target interception. Because bacterial membrane reorganization carries severe biological fitness costs, development of resistance against synthetic peptide antibiotics is statistically miniscule compared to classic beta-lactams or fluoroquinolones.
Engineered amphipathic alpha-helical and beta-sheet architectures tailored to electrostatically bind prokaryotic phosphatidylglycerol without disrupting zwitterionic eukaryotic mammalian membranes.
Potent penetration of extracellular polymeric substances (EPS). Effective clearance of recalcitrant biofilms common in catheter-associated UTIs, cystic fibrosis pulmonary infections, and surgical implants.
Synergistic neutralization of bacterial lipopolysaccharides (LPS) and endotoxin, suppressing systemic cytokine storms (sepsis prevention) while recruiting host immune effectors.
Continuous innovation in chemical peptide synthesis: Bridging Solid-Phase Peptide Synthesis (SPPS), Liquid-Phase Segment Condensation (LPPS), and Green Chemistry protocols.
How our integrated Hangzhou biomanufacturing facility mitigates global peptide drug shortages through vertical supply integration, automated SCADA systems, and multi-ton operational continuity.
Direct in-house synthesis of high-purity protected amino acids (Fmoc, Boc), specialized non-proteinogenic building blocks, pseudoprolines, and cleavage resins (CTC, Wang, Rink Amide).
Equipped with 500L to 3000L solid-phase reactors, industrial lyophilizers handling hundreds of kilograms per batch, and class 100,000 cleanrooms meeting international regulatory benchmarks.
In-line Near-Infrared (NIR) and mass-spec process analytical technologies track real-time reaction coupling and deprotection completeness, preventing accumulation of truncated contaminants.
Providing exhaustive chemistry, manufacturing, and controls (CMC) documentation aligned with US FDA (21 CFR Part 210/211), EMA, PMDA, and NMPA filing standards.
Every batch ships with comprehensive analytical characterization:
We provide open and closed Drug Master File (Type II DMF) components, assisting global generic formulation developers and innovative clinical sponsors through IND, NDA, and ANDA pathways without regulatory delay.
Strict environmental sanitation regimens ensure low bioburden levels (< 10 CFU/g) and verified bacterial endotoxin testing (Chromogenic LAL assay < 5 EU/mg), tailored specifically for sterile injectable dosages.
Procurement teams require price transparency, guaranteed lead times, cold-chain integrity, and localized communication channels across major economic corridors.
Supporting innovator biotechs and generic ANDA holders with technical dossiers, DDP delivery terms, and validated cold-chain transport (-20°C dry ice).
Bilingual operational management, simplified customs clearance assistance, and documentation compliant with EAEU GMP standards.
Rapid turn-around times for pilot commercial campaigns, customized salt conversions, and regional supply chain contingency coordination.
Dedicated export trade specialists handling high-demand GLP-1 analogues, metabolic APIs, and cosmetic peptides for private label formulators.
Detailed technical answers addressing purity verification, counter-ion control, CDMO timelines, and custom antibiotic peptide synthesis feasibility.
Browse our high-barrier peptide API catalog produced with industry-leading purity, high reproducibility, and dedicated documentation support for worldwide filing.
Thin